Why AI drug innovations are stalling before approval

New research suggests that the path from algorithm-driven drug discovery to real-world clinical success remains deeply constrained by scientific, technical, and regulatory barriers.

A new study titled "From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation," published in Pharmaceuticals, assesses how artificial intelligence (AI) is being deployed across the preclinical drug development pipeline and why many promising candidates fail to reach clinical stages.

AI transforms preclinical drug discovery but remains uneven in real-world impact

The study finds that AI is now deeply embedded across nearly every stage of preclinical drug discovery. From identifying potential drug targets to optimizing molecular structures and predicting toxicity, AI-driven systems are increasingly replacing or augmenting traditional trial-and-error methods.

At the earliest stage, AI models are being used to predict drug-target interactions with high speed and scale. Machine learning algorithms analyze biological datasets to identify how specific molecules interact with proteins, enabling researchers to narrow down viable candidates far more efficiently than conventional screening approaches. This capability has significantly reduced the time required to identify lead compounds.

Advances in protein structure prediction represent another major breakthrough. AI systems, particularly those based on deep learning, have improved the accuracy of modeling complex biological structures. This allows scientists to better understand how drugs bind to targets at a molecular level, improving the rational design of therapeutics.

The study also highlights the rise of de novo drug design, where generative AI models create entirely new molecular structures optimized for specific biological functions. These systems explore vast chemical spaces that would be impossible to navigate manually, opening new possibilities for discovering innovative treatments.

In parallel, AI is being applied to virtual screening processes, enabling the rapid evaluation of millions of compounds against target profiles. This dramatically increases the efficiency of identifying promising drug candidates while reducing reliance on costly laboratory experiments.

Drug repurposing has also emerged as a key application. AI systems analyze existing drugs and biological data to identify new therapeutic uses, offering a faster and lower-risk pathway compared to developing new compounds from scratch.

AI is playing a critical role in predicting pharmacokinetic and toxicity profiles. Models that estimate absorption, distribution, metabolism, excretion, and toxicity help researchers identify potential safety issues early in development, reducing the likelihood of late-stage failures.

Despite these advances, the impact of AI in real-world drug development remains uneven. While computational tools have accelerated early-stage discovery, the transition from laboratory insights to clinically viable therapies continues to face significant challenges.

Structural barriers limit the transition from AI discovery to clinical success

The research identifies a set of persistent barriers that prevent AI-driven discoveries from becoming approved medical treatments. These challenges span data quality, model reliability, biological complexity, and regulatory constraints.

• Data bias and fragmentation: AI models rely on large datasets for training, but available biological and chemical data are often incomplete, inconsistent, or skewed toward certain types of molecules and diseases. This limits the generalizability of predictions and increases the risk of failure when models are applied to new contexts.
• Model interpretability: Many advanced AI systems operate as black boxes, producing predictions without clear explanations of how decisions are made. This lack of transparency creates difficulties for researchers and regulators who need to validate findings and ensure safety before progressing to clinical trials.
• Computational predictions and biological reality: Even highly accurate models cannot fully capture the complexity of human physiology. Factors such as genetic variability, environmental influences, and disease heterogeneity introduce uncertainties that are difficult to model, leading to discrepancies between predicted and observed outcomes.
• Synthetic feasibility: While AI can generate novel molecular structures, not all proposed compounds can be easily synthesized in the laboratory. This disconnect between design and manufacturability slows the transition from theoretical discovery to experimental validation.
• Integrating AI into existing drug development workflows: Pharmaceutical pipelines are complex and highly regulated, and incorporating new technologies requires significant adjustments in infrastructure, expertise, and organizational processes.
• Regulatory uncertainty: Current frameworks for drug approval are not fully adapted to AI-driven discovery methods. Questions around validation standards, reproducibility, and accountability remain unresolved, creating additional hurdles for companies seeking to bring AI-designed drugs to market.

These barriers are not isolated but interconnected. Addressing them requires coordinated efforts across scientific research, industry practices, and policy development.

Toward a more integrated and translational AI-driven drug development ecosystem

To overcome these challenges, the study calls for a more integrated approach to AI-driven drug discovery, one that bridges the gap between computational innovation and clinical application.

• Improving data quality and accessibility: The development of standardized, high-quality datasets that capture diverse biological conditions can enhance model performance and reliability. Collaborative data-sharing initiatives between academia, industry, and healthcare institutions are seen as essential for achieving this goal.
• Enhancing model interpretability: Researchers are increasingly focusing on explainable AI techniques that provide insights into how predictions are generated. This can improve trust in AI systems and facilitate their acceptance in regulatory and clinical contexts.
• Hybrid approaches that combine AI with experimental validation: Rather than relying solely on computational predictions, integrating AI with laboratory testing can create more robust and reliable pipelines.
• Advances in multi-omics data integration are expected to play a key role in addressing biological complexity. By combining genomic, proteomic, and metabolomic data, AI systems can develop more comprehensive models of disease mechanisms and drug responses.
• Practically, improving the alignment between AI-generated designs and synthetic feasibility is essential. This involves incorporating chemical constraints and manufacturing considerations into generative models, ensuring that proposed compounds can be produced efficiently.
• Updated regulatory frameworks that can accommodate AI-driven methodologies. Clear guidelines for validation, transparency, and accountability will be crucial for accelerating the approval process while maintaining safety standards.
• Last but not least, interdisciplinary collaboration is also critical. Bringing together experts in artificial intelligence, chemistry, biology, and clinical research can help address the complex challenges of translating AI discoveries into real-world therapies.